Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 14;2010(4):CD007869.
doi: 10.1002/14651858.CD007869.pub2.

Interventions for non-metastatic squamous cell carcinoma of the skin

Louise Lansbury  1 , Jo Leonardi-Bee, William Perkins, Timothy Goodacre, John A Tweed, Fiona J Bath-Hextall
Affiliations

Interventions for non-metastatic squamous cell carcinoma of the skin

Louise Lansbury et al. Cochrane Database Syst Rev. .

Abstract

Background: Squamous cell carcinoma (SCC) is the second most common skin cancer, and is becoming increasingly common around the world. Left untreated, it may spread to other parts of the body, and, although the risk is low, it may ultimately lead to death. Surgical excision is the first line of treatment for most skin SCCs, although other forms of treatment are also used depending upon the nature and site of the tumour and individual participant factors. A multi-professional approach is therefore required for the management of people with this condition.

Objectives: To assess the effects of treatments for primary non-metastatic squamous cell carcinoma of the skin.

Search strategy: In February 2010 we searched for relevant trials in The Cochrane Skin Group Specialised Register, The Cochrane Library (Issue 1, 2010), MEDLINE, EMBASE, PsycINFO, AMED, LILACS, and the ongoing trials registries.

Selection criteria: We only included randomised controlled trials (RCTs) of interventions for primary SCC of the skin. Inclusion criteria were: adults with one or more histologically proven primary SCCs of the skin which had not metastasised. The primary outcome measures were time to recurrence one to five years after treatment, and quality of life. Secondary outcomes included early treatment failure within six months, number of adverse events by the end of treatment, aesthetic appearance as assessed by the participant and clinician, discomfort to the participant during and after treatment, and death.

Data collection and analysis: Two authors (LL, FB-H) independently carried out study selection and assessment of methodological quality and data extraction.

Main results: One trial involving 65 people was included. This compared the time to recurrence in participants with aggressive skin SCC who were randomised to receive either adjuvant 13-cis-retinoic acid and interferon alpha after surgery with or without radiation treatment, or no adjuvant therapy after their initial treatment. There was no significant difference in time to recurrence of tumour between the two groups (hazard ratio 1.08, 95% confidence intervals 0.43 to 2.72).Most studies identified from the searches were excluded as they were either uncontrolled case series, did not include participants with invasive primary SCC, or included only participants with recurrent or metastatic disease.

Authors' conclusions: Little evidence from RCTs comparing the efficacy of different interventions for primary cutaneous SCCs exists. There is a clear need for well-designed randomised studies in order to improve the evidence base for the management of this condition.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Forest plot of comparison: 1 13‐cis‐retinoic‐acid and interferon alfa vs no adjuvant therapy, outcome: 1.1 Time to recurrence.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 13‐cis‐retinoic‐acid and interferon alpha vs no adjuvant therapy, Outcome 1 Time to recurrence.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Brewster 2007 {published data only}
    1. Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, et al. Randomized trial of adjuvant 13‐cis‐retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007;25(15):1974‐8. - PubMed

References to studies excluded from this review

Brandt 2007 {published data only}
    1. Brandt MG, Moore CC, Jordan K. Randomized control trial of fluorescence‐guided surgical excision of nonmelanotic cutaneous malignancies. The Journal of Otolaryngology 2007;36(3):148‐55. - PubMed
Cham 1991 {published data only}
    1. Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Letters 1991;59(3):183‐92. - PubMed
Coates 1984 {published data only}
    1. Coates AS, Tattersall MH, Swanson C, Hedley D, Fox RM, Raghavan D. Combination therapy with methotrexate and 5‐fluorouracil: A prospective randomized clinical trial of order of administration. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1984;2(7):756‐61. - PubMed
Eedy 2003 {published data only}
    1. Eedy D. Immunomodulators in the treatment of skin cancer. Abstract S37‐6. The 12th Congress of the European Academy of Dermatology and Venereology. Barcelona, Spain 15‐18th October 2003. Journal of the European Academy of Dermatology and Venereology 2003;17(Suppl 3):49. - PubMed
Haas 1976 {published data only}
    1. Haas CD. Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer 1976;38(1):8‐12. - PubMed
Healy 1969 {published data only}
    1. Healy JB. The use of topical 5‐fluorouracil in the treatment of skin tumours ‐ Preliminary report. Journal of the Irish Medical Association 1969;62(380):41‐6. - PubMed
Landthaler 1989 {published data only}
    1. Landthaler M, Braun‐Falco O. TDF factors in soft x‐ray therapy [Anwendung des TDF‐Faktors in der Röntgenweichstrahlentherapie]. Hautarzt 1989;40:774‐777. - PubMed
Lui 2004 {published data only}
    1. Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light‐emitting diodes: Two‐year results evaluating tumor response and cosmetic outcomes. Archives of Dermatology 2004;140(1):26‐32. - PubMed
Moseley 1976 {published data only}
    1. Moseley HS, Sasaki T, McConnell DB, Merhoff GC, Wilson WL, Grage TB, et al. A randomized pilot study comparing two regimens in the treatment of squamous cell carcinoma. Journal of Surgical Oncology 1976;8(1):35‐42. - PubMed
MRC 1976 {published data only}
    1. Medical Research Council Working party on Bleomycin. Bleomycin in advanced squamous cell carcinoma: a random controlled trial. Report of Medical Research Council Working Party on Bleomycin. British Medical Journal 1976;1(6003):188‐90. - PMC - PubMed
Perez 1991 {published data only}
    1. Perez CA, Pajak T, Emami B, Hornback NB, Tupchong L, Rubin P. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. American Journal of Clinical Oncology 1991;14(2):133‐141. - PubMed
Radny 2006 {published data only}
    1. Radny P, Garbe C, Bruckner‐Tuderman L, Nashan D. Selective Electrochemical Tumour Ablation (SECTA) with Intralesional Bleomycin Abstract 6. 3rd meeting of the European Association of Dermato‐Oncology, Rome 23‐25 June 2006. Journal of Investigative Dermatology 2006;126(Suppl 2):S2. - PubMed
Seyss 1968 {published data only}
    1. Seyss R. On the practice of soft ray and proximity radiotherapy in skin and lip carcinomas [Zur Praxis der Weichstrahl‐ und Nahbestrahlungstherapie bei Haut‐ und Lippenkarzinomen]. Wiener Medizinische Wochenschrift 1968;118(2):34‐6. - PubMed

References to ongoing studies

TROG 05.01 {unpublished data only}
    1. Post‐operative concurrent chemo‐radiotherapy (Carboplatin) versus post‐operative radiotherapy in high‐risk cutaneous squamous cell carcinoma of the head and neck to improve loco‐regional relapse.. Ongoing study 20/4/05.

Additional references

Alam 2001
    1. Alam M, Ratner D. Primary care: Cutaneous squamous‐cell carcinoma. New England Journal of Medicine 2001;344(13):975‐983. - PubMed
Albrecht 2008
    1. Albrecht J, Bigby M. What makes a good case series?. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B editor(s). Evidence‐Based Dermatology. Second Edition. Blackwell Publishing, 2008:56‐60.
Altman 1991
    1. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
Armstrong 2001
    1. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. Journal of Photochemistry and Photobiology B:Biology 2001;63(1‐3):8‐18. - PubMed
Auerbach 1961
    1. Auerbach H. Geographic variation in incidence of skin cancer in the United States. Public Health Reports 1961;76(4):345‐8. - PMC - PubMed
Bath‐Hextall 2007
    1. Bath‐Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858] - DOI - PubMed
Black 1996
    1. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215‐1218. - PMC - PubMed
Bouwes Bavinck 1996
    1. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, Macnaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: A follow‐up study. Transplantation 1996;61(5):715‐721. - PubMed
Buettner 1998
    1. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville Australia. International Journal of Cancer 1998;78(5):587‐93. - PubMed
Cherpelis 2002
    1. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatologic Surgery 2002;28:268‐73. - PubMed
DeHertog 2001
    1. Hertog SAE, Wensveen CA, Bastiaens MT, Kielich CJ, Berkhout MJP, Westendorp RGJ. Relation between smoking and skin cancer. Journal of Clinical Oncology 2001;19(1):231‐8. - PubMed
Demopoulos 2003
    1. Demopoulos BP, Vamvakas E, Ehrlich JE, Demopoulos R. Non‐acquired immunodeficiency syndrome‐defining malignancies in patients infected with human immunodeficiency virus. Archives of Pathology and Laboratory Medicine 2003;127(5):589‐92. - PubMed
Diepgen 2002
    1. Diepgen TL, Mahler V. The epidemiology of skin cancer. British Journal of Dermatology 2002;146(Suppl 61):1‐6. - PubMed
Dinehart 1989
    1. Dinehart SM, Pollack SV. Metastases from squamous cell carcinoma of the skin and lip. Journal of the American Academy of Dermatology 1989;21:241‐8. - PubMed
Fine 1999
    1. Fine JD, Johnson LB, Suchidran C, Bauer EA, Carter DM, McGuire J. Cancer and inherited epidermolysis bullosa: Lifetable analyses of the National Epidermolysis Bullosa Registry study population. In: Fine JD, Bauer EA, McGuire J, Moshell A editor(s). Epidermolysis bullosa: Clinical, epidemiologic, and laboratory advances, and the findings of the national epidermolysis bullosa registry. Baltimore: John Hopkins University Press, 1999:175‐192.
Gallagher 1995
    1. Gallagher RP, Hill GB, Bajdik CD, Coldman AJ, Fincham S, McLean DI, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer:II. Squamous cell carcinoma. Archives of Dermatology 1995;131:164‐9. - PubMed
Glass 1989
    1. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. Journal of the American Medical Association 1989;262(15):2097‐100. - PubMed
Gloster 1996
    1. Gloster HM, Brodland DG. The epidemiology of skin cancer. Dermatologic Surgery 1996;22(3):217‐26. - PubMed
Gloster 2006
    1. Gloster HM, Neal K. Skin cancer in skin of color. Journal of the American Academy of Dermatology 2006;55(5):741‐760. - PubMed
Government 1997
    1. Department of Health. The New NHS: modern, dependable. London. The Stationery Office Ltd 1997:Clause 1.13.
Green 1996
    1. Green A, Battistutta D, Hart V, Leslie D, Weedon D. Skin cancer in a sub‐tropical Australian population: Incidence and lack of association with occupation. American Journal of Epidemiology 1996;144(11):1034‐40. - PubMed
Halder 1995
    1. Halder RM, Bridgeman‐Shah S. Skin cancer in African Americans. Cancer 1995;75(2):667‐73. - PubMed
Hardie 1980
    1. Hardie IR, Strong RW, Hartley LC, Woodruff PW, Clunie GJ. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980;87(2):177‐83. - PubMed
Hartevelt 1990
    1. Hartevelt MM, Bouwes Bavinck JN, Kootte AM, Vermeer BI, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49(3):506‐9. - PubMed
Harwood 2002
    1. Harwood CA, Proby CM. Human papillomaviruses and non‐melanoma skin cancer. Current Opinion in Infectious Diseases 2002;15(2):101‐114. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org 2008.
Holme 2000
    1. Holme SA, Malinovszky K, Roberts DL. Changing trends in non‐melanoma skin cancer in South Wales 1988‐98. British Journal of Dermatology 2000;143(6):1224‐9. - PubMed
Jensen 1999
    1. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long‐term immunosuppressive therapy regimens. Journal of the American Academy of Dermatology 1999;40:177‐86. - PubMed
Johnson 1992
    1. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). Journal of the American Academy of Dermatology 1992;26(3):467‐84. - PubMed
Kao 1986
    1. Kao GF. Carcinoma arising in Bowen's disease. Archives of Dermatology 1986;122(10):1124‐6. - PubMed
Karagas 2006
    1. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, et al. Human papillovirus infection and incidence of squamous cell and basal cell carcinomas of the skin. Journal of the National Cancer Institiute 2006;98(6):389‐395. - PubMed
Karagas 2007
    1. Karagas MR, Nelson HH, Zens MS, Linet M, Stukel TA, Spencer S, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology 2007;18(6):776‐84. - PubMed
Katz 2002
    1. Katz KA, Marcil I, Stern RS. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet light‐treated psoriasis patients. Journal of Investigative Dermatology 2002;118(6):1038‐43. - PubMed
Leong 1987
    1. Leong GK, Stone JL, Farmer ER, Scotto J, Reizner GT, Burnett TS, et al. Nonmelanoma skin cancer in Japanese residents of Kauai, Hawaii. Journal of the American Academy of Dermatology 1987;17:233‐8. - PubMed
Lim 2005
    1. Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non‐melanoma skin cancer in psoralen and ultraviolet A‐treated patients. Journal of Investigative Dermatology 2005;124(3):505‐13. - PubMed
London 1995
    1. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JPA. Risk of neoplasia in renal transplant patients. The Lancet 1995;346:403‐06. - PubMed
Marks 1986
    1. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: The case for conservative management. British Journal of Dermatology 1986;115(6):649‐55. - PubMed
Marks 1996
    1. Marks R. Squamous cell carcinoma. Lancet 1996;347(9003):735‐8. - PubMed
May 1981
    1. May GS, Demets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: Bias in analysis. Circulation 1981;64:669‐73. - PubMed
Miller 1994
    1. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. Journal of the American Academy of Dermatology 1994;30(5):774‐80. - PubMed
Moloney 2006
    1. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population‐based study of skin cancer incidence and prevalence in renal transplant recipients. British Journal of Dermatology 2006;154:498‐504. - PubMed
Mora 1981
    1. Mora RG, Perniciaro C. Cancer of the skin in blacks.I. A review of 163 black people with cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology 1981;5(5):535‐43. - PubMed
Motley 2002
    1. Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. British Journal of Dermatology 146;1:18‐25. - PubMed
Naldi 2000
    1. Naldi L, Fortina AB, Lovati S, Barba A, Gotti E, Tessari G, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry‐based study. Transplantation 2000;70(10):1479‐1484. - PubMed
Nijsten 2003
    1. Nijsten TEC, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: A cohort study. Journal of Investigative Dermatology 2003;121(2):252‐8. - PubMed
Parmar 1998
    1. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Pennello 2000
    1. Pennello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiology Biomarkers and Prevention 2000;9:291‐7. - PubMed
Peterka 1961
    1. Peterka ES, Lynch FW, Goltz RW. An association between Bowen's Disease and internal cancer. Archives of Dermatology 1961;84:623‐9. - PubMed
Preston 1992
    1. Preston DS, Stern RS. Nonmelanoma cancers of the skin. New England Journal of Medicine 1992;327(23):1649‐62. - PubMed
Ramsay 2002
    1. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Non‐melanoma skin cancer risk in the Queensland renal transplant population. British Journal of Dermatology 2002;147:950‐956. - PubMed
Rowe 1992
    1. Rowe DE, Carroll RJ, Day Jr CJ. Prognostic factors for local recurrence, metastasis and survival rates in squamous cell carcinoma of the skin, ear and lip: Implications for treatment modality selection. Journal of the American Academy of Dermatology 1992;26:976‐90. - PubMed
Sackett 1979
    1. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. New England Journal of Medicine 1979;301:1410‐12. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ. Empirical evidence of bias. Journal of the American Medical Academy 1995;273:408‐12. - PubMed
Scotto 1981
    1. Scotto J, Fears TR, Fraumeni JF Jr. Incidence of nonmelanoma skin cancer in the United States. Washington (DC): U.S. Government Printing Office, 1981. National Cancer Institute, DHSS Report No. NIH 82‐2433 1981.
Sober 1983
    1. Sober AJ. Diagnosis and management of skin cancer. Cancer 1983;51(12 Suppl):2448‐52. - PubMed
Staples 2006
    1. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non‐melanoma skin cancer in Australia: The 2002 national survey and trends since 1985. Medical Journal of Australia 2006;184(1):6‐10. - PubMed
Stranc 1987
    1. Stranc MF, Fogel M, Dische S. Comparison of lip function: Surgery vs radiotherapy. British Journal of Plastic Surgery 1987;40(6):598‐604. - PubMed
Weinstock 1993
    1. Weinstock MA. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Archives of Dermatology 1993;129:1286‐90. - PubMed
Yu 2006
    1. Yu H‐S, Liao W‐T, Chai C‐Y. Arsenic carcinogenesis in the skin. Journal of Biomedical Science 2006;13(5):657‐66. - PubMed

Publication types

MeSH terms